Question 1

What is MIRVETUXIMAB SORAVTANSINE used for?

Accepted Answer

MIRVETUXIMAB SORAVTANSINE (brand name ELAHERE) is a Other indicated for 1 INDICATIONS AND USAGE ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube.

Question 2

How does MIRVETUXIMAB SORAVTANSINE work?

Accepted Answer

MIRVETUXIMAB SORAVTANSINE works through the following mechanism: 12.1 Mechanism of Action Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death..

Question 3

What are the most common side effects of MIRVETUXIMAB SORAVTANSINE?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for MIRVETUXIMAB SORAVTANSINE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is MIRVETUXIMAB SORAVTANSINE the same as ELAHERE?

Accepted Answer

ELAHERE is a brand name for MIRVETUXIMAB SORAVTANSINE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

MIRVETUXIMAB SORAVTANSINE

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations